A possible role of p73 on the modulation of p53 level through MDM2 - PubMed (original) (raw)

. 2001 Feb 15;61(4):1598-603.

Affiliations

PMID: 11245471

A possible role of p73 on the modulation of p53 level through MDM2

X Q Wang et al. Cancer Res. 2001.

Abstract

MDM2, one of the transcriptional targets of p53, can target p53 for degradation in a negative feedback loop. The p53-related protein p73, however, can bind to MDM2 but is not consequently down-regulated. Here we demonstrate that p73 could transactivate the MDM2 promoter in p53-null cell lines. In p53-null cell lines, the level of MDM2 was increased by p73 due to increases in transcription and protein stability of MDM2. In transient transfection assays, inhibition of the transcriptional activity of p73 required a higher amount of MDM2 than that of p53. This is probably due to the fact that MDM2 can target p53, but not p73, for degradation. We demonstrated further that the level of p53 could be altered by a cooperation between MDM2 and p73, but not by transcriptional inactive mutants of p73. Expression of p73 resulted in a reduction of the ectopically expressed p53 in transient transfections or of the endogenous p53 induced by Adriamycin- or UV-mediated damage. These reductions of p53 were likely to be due to an increase in MDM2-mediated proteolysis. These results suggest the possibility that different levels of p73 in the cell may act as a mechanism to modulate p53 responses after DNA damage and other stresses and that an increase rather than a decrease in p73 may play a role in tumorigenesis.

PubMed Disclaimer

Cited by

p53-Related Transcription Targets of TAp73 in Cancer Cells-Bona Fide or Distorted Reality?
Wang C, Teo CR, Sabapathy K. Wang C, et al. Int J Mol Sci. 2020 Feb 17;21(4):1346. doi: 10.3390/ijms21041346. Int J Mol Sci. 2020. PMID: 32079264 Free PMC article. Review.
Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma.
Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Li C, et al. J Invest Dermatol. 2008 Jun;128(6):1585-8. doi: 10.1038/sj.jid.5701186. Epub 2007 Nov 29. J Invest Dermatol. 2008. PMID: 18049450 Free PMC article. No abstract available.
MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM, Biderman L, Tong D, Alaghebandan B, Plumber SA, Mueller HS, van Vlimmeren A, Katz C, Prives C. Klein AM, et al. Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2102420118. doi: 10.1073/pnas.2102420118. Proc Natl Acad Sci U S A. 2021. PMID: 34716260 Free PMC article.
p73 is required for vessel integrity controlling endothelial junctional dynamics through Angiomotin.
Maeso-Alonso L, Alonso-Olivares H, Martínez-García N, López-Ferreras L, Villoch-Fernández J, Puente-Santamaría L, Colas-Algora N, Fernández-Corona A, Lorenzo-Marcos ME, Jiménez B, Holmgren L, Wilhelm M, Millan J, Del Peso L, Claesson-Welsh L, Marques MM, Marin MC. Maeso-Alonso L, et al. Cell Mol Life Sci. 2022 Oct 1;79(10):535. doi: 10.1007/s00018-022-04560-3. Cell Mol Life Sci. 2022. PMID: 36180740 Free PMC article.
Targeting MDM2 for novel molecular therapy: Beyond oncology.
Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Wang W, et al. Med Res Rev. 2020 May;40(3):856-880. doi: 10.1002/med.21637. Epub 2019 Oct 6. Med Res Rev. 2020. PMID: 31587329 Free PMC article. Review.

A possible role of p73 on the modulation of p53 level through MDM2 - PubMed (original) (raw)